Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937458 | 0.89 | RXFP1 (0.62) | MAPTKMT2AMEN1RXFP1HTT | |
| SCHEMBL20164019 | 0.88 | RXFP1 (0.50) | MAPTKMT2AMEN1RXFP1LMNA | |
| SCHEMBL20164021 | 0.85 | KDM4E (0.49) | MAPTKMT2AMEN1RXFP1LMNA | |
| SCHEMBL18227081 | 0.83 | MAPT (0.53) | MAPTKMT2AMEN1LMNAMAPK1 | |
| SCHEMBL15452568 | 0.82 | RXFP1 (0.67) | MAPTKMT2AMEN1RXFP1HTT | |
| SCHEMBL28222179 | 0.78 | KMT2A (0.51) | MAPTKMT2AMEN1RXFP1LMNA | |
| SCHEMBL9936723 | 0.75 | KDM4E (0.55) | MAPTKMT2AMEN1RXFP1MAPK1 | |
| SCHEMBL15452564 | 0.73 | RXFP1 (0.73) | MAPTKMT2AMEN1RXFP1KDM4E | |
| SCHEMBL28222883 | 0.72 | POLB (0.54) | MAPTKMT2AMEN1LMNAMAPK1 | |
| SCHEMBL29635287 | 0.72 | MEN1 (0.50) | MAPTKMT2AMEN1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3304088-B1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LTD (GB) | 2025-07-30 | — | — | EP | claimed |
| EP-3304088-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | Electrophoretics Limited (GB) | 2018-04-11 | — | — | EP | claimed |
| US-9763947-B2 | Casein kinase 1delta (CK1delta) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-09-19 | — | — | US | claimed |
| WO-2016189163-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LIMITED (GB) | 2016-12-01 | — | — | WO | claimed |
| CN-105920010-A | Casein Kinase 1delta (ck 1delta) Inhibitors | 电泳有限公司 | 2016-09-07 | — | — | CN | claimed |
| CN-103298460-B | Casein kinase 1(CK1) inhibitors | ELECTROPHORETICS LTD. (GB) | 2016-06-01 | — | — | CN | claimed |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2016-03-03 | — | — | US | claimed |
| EP-2651404-B1 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | ELECTROPHORETICS LTD (GB) | 2015-10-14 | — | — | EP | claimed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | claimed |
| EP-2651404-A2 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | Electrophoretics Limited (GB) | 2013-10-23 | — | — | EP | claimed |
| CN-103298460-A | Casein kinase 1 delta (CK1 delta) inhibitors | ELECTROPHORETICS LTD | 2013-09-11 | — | — | CN | claimed |
| WO-2012080727-A2 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2012-06-21 | — | — | WO | claimed |
| US-20260091025-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LIMITED (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4663754-A2 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | Electrophoretics Limited (GB) | 2025-12-17 | — | — | EP | disclosed |
| US-12419871-B2 | Biomolecules involved in Alzheimer's disease | ELECTROPHORETICS LIMITED (GB) | 2025-09-23 | — | — | US | disclosed |
| EP-3304088-B1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LTD (GB) | 2025-07-30 | — | — | EP | disclosed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | disclosed |
| EP-2651404-A2 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | Electrophoretics Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| CN-103298460-A | Casein kinase 1 delta (CK1 delta) inhibitors | ELECTROPHORETICS LTD | 2013-09-11 | — | — | CN | disclosed |
| WO-2012080727-A2 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1G1, CSNK1A1, CSNK1D | MAPT 56/4885KMT2A 695/4885MEN1 3434/4885 |
| US-20260091025-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | PYGB, PACSIN2, PPP3CA | MAPT 25/4885KMT2A 3313/4885MEN1 4544/4885 |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1A1, CSNK1G1, CSNK1D | MAPT 60/4885KMT2A 656/4885MEN1 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.